miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2

Table 1 Clinical and pathological information of patients

Number	ID	Age (year)	Tsize (mm)	Lymph node metastasis	Grade	AJCC anatomic stage	ER	PR	HER2	Subtype
1	1,595,476	35	30	0	3	2A	N	N	N	Triple negative
2	1,597,702	44	25	0	3	2A	N	N	N	Triple negative
3	1,613,380	39	25	0	3	2A	N	N	N	Triple negative
4	1,561,558	47	30	0	2	2A	N	N	N	Triple negative
5	1,593,213	71	30	0	1	2A	N	N	N	Triple negative
6	1,558,369	67	45	2	3	2B	N	N	P	Her2 overexpressing
7	1,562,676	46	22	0	3	2A	N	N	P	Her2 overexpressing
8	1,568,640	72	25	3	3	2B	N	N	P	Her2 overexpressing
9	1,538,312	73	15	0	2	1A	P	P	N	Luminal A
10	1,538,856	59	40	3	3	2B	P	P	N	Luminal A
11	1,540,806	54	30	1	2	2B	P	P	N	Luminal A
12	1,557,688	61	15	0	2	1A	P	P	N	Luminal A
13	1,563,656	43	30	1	3	2B	P	P	N	Luminal A
14	1,594,881	44	20	0	2	1A	P	P	N	Luminal A
15	1,558,066	49	15	0	2	1A	P	P	N	Luminal A
16	1,547,013	62	15	0	1	1A	P	P	N	Luminal A
17	1,551,621	49	20	0	2	2A	P	P	N	Luminal A
18	1,554,600	74	20	2	3	2B	P	P	N	Luminal A
19	1,540,752	48	20	1	2	2B	P	P	P	Luminal B
20	1,545,637	44	50	13	3	3C	P	P	P	Luminal B
21	1,589,813	35	18	1	2	2A	P	P	N	Luminal A
22	1,595,773	64	27	0	1	2A	P	P	N	Luminal A
23	1,595,546	47	30	13	3	4	P	P	P	Luminal B
24	1,596,351	45	63	0	3	2B	P	P	P	Luminal B
25	1,608,794	39	25	0	3	2A	P	P	N	Luminal A
26	1,609,339	52	30	12	3	3C	P	P	N	Luminal A
27	1,612,095	67	20	3	2	2B	P	P	N	Luminal A
28	1,595,081	39	30	22	3	3C	P	P	N	Luminal A

AJCC American Joint Committee on Cancer, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, N negative, P positive, PR progesterone receptor, Tsize tumor size

ISSN: 1756-9966